Dupixent (dupilumab) has been a breakthrough treatment for people with severe eczema, asthma, and other inflammatory ...
The first patient with relapsed or refractory CD5-positive T-cell lymphoma has been dosed with the CAR-T cell therapy MB-105. The first patient with relapsed or refractory CD5-positive T-cell lymphoma ...
Patients treated with mogamulizumab showed a trend toward improved OS compared to those not receiving mogamulizumab across risk-stratified groups according to the new Cutaneous Lymphoma International ...
Brexucabtagene autoleucel approval marked a significant advancement in MCL treatment, achieving a 62% complete remission rate in resistant or relapsed patients. Prognostic tools like the Ki-67 index ...
From relapse to remission: Groundbreaking therapy gives Non-Hodgkin’s Lymphoma patients renewed hope
Doctors are turning to a groundbreaking new therapy; one that’s not only giving patients more healthy years, but in some ...
A live webcast of the presentation will be accessible via Caribou’s website on the Events page. The archived webcast will be available on the Caribou website for 30 days after the event. About ...
By analyzing the tumor environment of diffuse large B-cell lymphoma (DLBCL), researchers from The University of Texas MD ...
Adult T-cell leukemia–lymphoma (ATL) is a peripheral T-cell malignancy, closely associated with human T-cell lymphotropic virus type I infection. Clinically, ATL is classified into four subtypes: ...
Regeneron has given up on a CAR-T candidate acquired from 2seventy bio last year before it entered the second part of a phase 1/2 lymphoma study. | Regeneron has given up on a CAR-T candidate acquired ...
The discontinued CAR T therapy bbT369 came to Regeneron when the pharma bought all of 2seventy bio’s pipeline assets for $5 ...
The integration of Bruton tyrosine kinase (BTK) inhibitors into first-line treatment regimens, in combination with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback